Stephen J Davies

Summary

Affiliation: Evotec OAI

Publications

  1. ncbi Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the methylene spacer and the P1' side chain
    Stephen J Davies
    British Biotech Pharmaceuticals Limited, Watlington Road, Oxford OX4 6LY, UK
    Bioorg Med Chem Lett 13:2709-13. 2003
  2. ncbi Structure--activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2' and P3' side chains
    Stephen J Davies
    British Biotech Pharmaceuticals Limited, Watlington Road, Oxford OX4 6LY, UK
    Bioorg Med Chem Lett 13:2715-8. 2003
  3. ncbi Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin
    Hinrich P Hansen
    Department of Biochemistry, University of Kiel, Kiel, Germany
    Int J Cancer 98:210-5. 2002

Collaborators

  • J M Clements
  • Hinrich P Hansen
  • Regina Foelster-Holst
  • Hans H Lange
  • Andreas Engert
  • R Paul Beckett
  • Hilmar Lemke
  • Bärbel Matthey
  • Thilo Mokros
  • Stefan Barth
  • Tatiana Kisseleva

Detail Information

Publications3

  1. ncbi Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the methylene spacer and the P1' side chain
    Stephen J Davies
    British Biotech Pharmaceuticals Limited, Watlington Road, Oxford OX4 6LY, UK
    Bioorg Med Chem Lett 13:2709-13. 2003
    ..Additionally, lipophilic P1' side chains that closely mimic the methionine residue in the substrate provided compounds with the best microbiological profile...
  2. ncbi Structure--activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2' and P3' side chains
    Stephen J Davies
    British Biotech Pharmaceuticals Limited, Watlington Road, Oxford OX4 6LY, UK
    Bioorg Med Chem Lett 13:2715-8. 2003
    ..The data from this study highlights the potential for modification at the P2' and P3' positions to optimise the physicochemical properties...
  3. ncbi Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin
    Hinrich P Hansen
    Department of Biochemistry, University of Kiel, Kiel, Germany
    Int J Cancer 98:210-5. 2002
    ..dgA towards the CD30(+) Hodgkin-derived cell line L540. Hence, the metalloproteinase inhibitor BB-3644 may be a promising compound to improve the immunotherapy of CD30(+) malignancies...